INTRODUCTION
Endometrial cancer is the eighth leading cause of cancer-related death among American women (1) . At presentation, the vast majority of tumors are endometrioid endometrial cancers (EECs), which are estrogen-dependent tumors that may be preceded by endometrial intraepithelial neoplasia, a premalignant outgrowth from hormonally-induced, benign endometrial hyperplasia (2) . Most EECs are detected at an early stage when surgery is an effective form of treatment (3) . The clinical management of recurrent and advanced disease includes surgery, followed by chemotherapy or radiotherapy alone or in combination (4) . However, the prognosis for women with recurrent or advanced stage EECs is relatively poor (5, 6) and alternative therapeutic options are needed.
In contrast to EECs, non-endometrioid endometrial cancers (NEECs) are high-grade, estrogen-independent tumors that arise from the atrophic endometrium in postmenopausal women (7) . NEECs are clinically aggressive and have a significantly worse prognosis than EECs even when corrected for tumor stage (5, 6) . Current therapeutic strategies to manage NEECs are variable but generally include surgery and adjuvant therapy, even in cases of early-stage disease (4, 8) . Although NEECs represent a minority (5-10%) of cases at presentation, they account for a disproportionate number of all endometrial cancer-related deaths (5) . Thus, there is a critical need for improved therapeutic options for patients with this tumor subtype.
PI3Kα-mediated signaling is frequent in human cancers, resulting in increased AKTdependent or AKT-independent signaling and leading to increased cell proliferation, growth, survival and migration (10, 11). The pathway is antagonized by the activity of the PTEN phosphatase (12) (13) (14) .
A number of pharmacological agents targeting components of the PI3K signal transduction pathway have been developed (9, 15) . These include PI3K inhibitors, AKT inhibitors, and inhibitors of downstream effectors such as mTOR (mammalian target of rapamycin), a serine-threonine kinase that mediates PI3K-AKT signaling (9) . A number of PI3K-pathway inhibitors have already entered clinical trials, including trials to assess efficacy in endometrial cancer patients (16) (17) (18) (19) .
Common mechanisms of PI3Kα activation in tumorigenesis are the acquisition of somatic gain-of-function mutations within PIK3CA (20) , or loss of PTEN activity resulting from mutations or gene deletion (12, 14) . Early studies of colorectal, breast, ovarian, and bladder cancers, in which all coding exons of PIK3CA were sequenced, revealed that ~80% of all PIK3CA mutations occurred within exons 9 and 20, which encode the C-terminal helical and kinase domains of p110α (20) (21) (22) . A much smaller fraction (~ 20%) of PIK3CA mutations in these tumors were within exons 1-7, which encode the N-terminal domains of p110α including the p85/adaptor-binding domain (ABD) and the protein kinase-C homology 2 (C2) domain (23) .
6 mutations in other exons of PIK3CA in endometrial tumors has not been rigorously defined.
Interestingly however, one study noted a disproportionate number of exon 1 mutations (4 of 6 mutations) in a small series of endometrial cancer cell-lines (33) . Another study of primary sporadic EECs observed that 4 of 9 PIK3CA mutations in EECs were in exon 1 (34). Because the frequency of amino terminal p110α mutants relative to carboxy-terminal domain mutants was relatively high in these two studies, we hypothesized that endometrial carcinomas might have a different spectrum of PIK3CA mutations compared with other tumor types. Given the therapeutic importance of altered PI3Kα-mediated signaling, we therefore sought to rigorously define the overall frequency and distribution of somatic PIK3CA mutations in a large series of 108 primary endometrial cancers comprised of EECs and NEECs.
Here we show that in both EECs and NEECs, PIK3CA mutations are as frequent within exons 1-7 as within exons 9-20. Almost all exon 1-7 mutations clustered within three specific regions of p110α, the ABD, the ABD-RBD linker and the C2 domain. Our study revealed three major mutational hotspots at amino acids 88, 93 and 111 within the ABD and its adjacent linker. We extended our study to investigate the biochemical properties of ten previously uncharacterized PIK3CA mutants within exons 1-7. Six of the ten mutations tested encoded gain-of-function p110α mutants that increased levels of phospho-AKT(Ser473), compared to wildtype p110α. Overall, 62% of all mutations in exons 1-7 encoded gain-offunction mutants of p110α. We further show that, like PIK3CA exon 9-20 mutations, 
MATERIALS AND METHODS

Clinical material
Snap-frozen primary tumor tissues, corresponding hematoxylin and eosin (H&E)-stained tumor sections, and matched normal tissues, were obtained from the Cooperative Human Tissue Network, which is funded by the National Cancer Institute, or from the Biosample Repository at Fox Chase Cancer Center, Philadelphia PA. Matched tumor and normal DNAs for six cases were purchased from Oncomatrix. Tumor specimens were collected at surgical resection, prior to treatment. Tumors were selected for endometrioid (n=42), serous (n=46) and clear cell (n=20) histologies. A histological classification was rendered based upon the entire specimen at time of diagnosis. Matched normal tissues were uninvolved reproductive tissue or whole blood. All tissues, and accompanying clinicopathological information, were anonymized and collected with appropriate IRB approval. A pathologist compared the H&E section to the original classification to verify that it was representative histologically, and to delineate regions of tissue comprised of >70% tumor cells for macrodissection.
DNA extraction and identity testing
Genomic DNA was isolated from macrodissected tumor tissues and normal tissues using the PUREGENE kit (Qiagen). To confirm that tumor-normal pairs were derived from the same individual, each DNA sample was typed using the Coriell Identity Mapping kit (Coriell). Genotyping fragments were resolved on an ABI-3730xl DNA analyzer (Applied Biosystems) and scored using GeneMapper software.
Research. Sequencing products were ethanol precipitated and resolved on an ABI-3730xl DNA analyzer (Applied Biosystems). Tumor sequences were aligned to a reference sequence using 
Statistical analyses
All comparisons between groups were performed using a 2-tailed Fisher's Exact test of significance.
Mammalian cell culture
The U2OS human osteosarcoma cell line was maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen), at 37°C, in a humidified atmosphere. 
Generation of expression constructs
A baculovirus expression construct containing the full-length, wild-type, PIK3CA cDNA cloned into the pFastBac vector (Invitrogen), was a kind gift from Dr. Yardena Samuels (NHGRI/NIH). This construct was used as a template to generate a series of PIK3CA mutant constructs by site directed mutagenesis using the QuikChange II XL SiteDirected Mutagenesis Kit (Stratagene), according to the manufacturer's instructions. The mutations created corresponded to the R93Q, R93W, G106R, G106V, K111E, E453A, E453K, E365K, G364R, H1047R, and delP449-455 mutants of p110α. Wild-type and mutant PIK3CA inserts were excised using BamHI and HindIII and subcloned into the FLAG-tagged pCMV-3Tag-1A expression vector (Agilent Technologies). Sanger sequencing was used to confirm the integrity of the cloning sites and the PIK3CA inserts.
Transfections, and western blotting
U2OS cells were transfected with vector, wild-type, or mutant expression constructs using FuGENE-6 transfection reagent (Roche), according to the manufacturer's protocol.
Stably transfected cells were selected in the presence of 1000μg/ml G418 (Invitrogen). For western blots, pools of stably selected cells were serum starved in DMEM containing 0.5%FBS for 15hr and lysed in lysis buffer (1% TritonX-100, 150mM NaCL, 50mM Tris-HCL pH 7.4, 1mM EDTA, 1mM Na-orthovanadate, 10mM NaF, 1X protease inhibitor cocktail (Roche)). Lysates were centrifuged at 4°C for 10min at 12,000xg to remove insoluble cellular debris and denatured at 95°C in 2X SDS sample buffer (Sigma) for 5min prior to electrophoresis. Denatured proteins (20-40μg) were resolved with SDS-PAGE and recurrently mutated residues, R88, R93, and K111, formed hotspots that together accounted for 22% (13 of 58) of all exonic mutations in this study.
Among the 29 individual mutations in exons 1-7, 20 mutations were unique. Five of 20 (25%) unique mutations, namely R88Q, K111N, R108H, E365K, and C420R, are known to encode gain-of-function mutants of p110α (33, 37) . The remaining 15 unique mutations have not been functionally characterized. Of these uncharacterized mutations, nine (E81K, R93W, R93Q, G106V, delE109, K111E, G118D, V344A, and E453K), were either recurrent within this study, or were recurrent between this study and other studies (35) , suggesting that they might confer a selective advantage in tumorigenesis. The six remaining uncharacterized mutations were novel. Two of the novel mutations (delL15_V22insHPI and G106R) localized to the ABD of p110α, one (A222V) localized to the RBD, and three (G364R, delP449-L445, E453A) localized to the C2 domain. Three novel mutations (delL15_V22insHPI, G106R, delP449-L445, E453A) involved amino acids that undergo a different mutation here or in other studies (31) . 
M1040L, M1004F
, and Q546P), have not previously been observed in endometrial tumors (35) . Of these four mutations, one (Q546P) is a known gain-of function mutation that is present in seven tumors from other anatomical sites (35, 37) . 
Patterns of
contrast, the most frequently observed mutation pattern in NEECs was single mutants of PIK3CA, which accounted for 24.2% (16 of 66) of all cases.
In a previous study of endometrial cancers there was a tendency for PIK3CA exons 9 and 20 mutations to be more frequent in PTEN-mutant tumors than in PTEN wildtype tumors (26) . Here, we evaluated the pattern of PIK3CA exons 1-20 mutations and PTEN mutations within EECs wherein the incidence of PTEN mutations was 7.4-fold higher than in NEECs.
We observed no significant difference in the frequency of PIK3CA mutations among PTEN mutant EECs (51.5%, 17 of 33) and PTEN wild-type EECs (55.5%, 5 of 9) (P=1.0).
PIK3CA and KRAS mutations coexisted in 19% (8 of 42) of EECs and in 1.5% (1 of 66) of NEECs in our study. Given the higher frequency of KRAS mutations in EECs than in
NEECs in this study, we evaluated PIK3CA and KRAS mutation patterns in EECs. We observed no significant difference in the frequency of KRAS mutations between PIK3CA wild-type EECs and PIK3CA mutant EECs (50% (10 of 20) versus 36.4% (8 of 22) respectively) (P=0.53). Although there was a tendency for KRAS mutations to be present more often in PTEN mutant EECs (48.5%, 16 of 33) than in PTEN wild-type EECs (22%, 2 of 9 cases), the difference was not statistically significant (P=0.26).
Functional characterization of ABD, ABD-RBD, and C2 domain mutants
Because we observed that PIK3CA exon 1-7 mutations were significantly higher in our series of endometrial tumors than in other tumor types, we sought to determine the functional consequences of a subset of exon 1-7 mutations identified here. Eight of the 15 uncharacterized mutations in these exons were distributed among four recurrently mutated residues (R93, G106, K111, E453) of p110α in our tumor series. We hypothesized that these particular mutations might be functionally significant. We therefore sought to determine the functional significance of the R93W, R93Q, G106R, G106V, K111E, E453A, E453K, delP449-L455 mutants, that together encompass the four recurrently mutated amino acids, as well as the V344A and G364R mutants within the C2 domain.
We examined the ability of each of the p110α mutants to phosphorylate AKT on Serine-473 ( Ser473 ) in stably transfected U2OS (osteosarcoma) cells. We chose U2OS cells because they have low endogenous levels of phospho-AKT, and because they have previously been used to evaluate the activity of other p110α mutants (33) . Two known gainof-function mutants, p110α-E365K (a C2 domain mutant) and p110α H1047R (a kinase domain mutant), were included as positive controls for AKT activation (10, 33).
Under low serum conditions, we observed that the exogenous expression of six mutants, p110α-R93W, -G106R, -G106V, -K111E, -delP449-L455, and -E453K, led to increased levels of phospho-AKT Ser473 compared to the wild-type p110α (Figure 2A and 2B ).
These six mutations account for 27% (8 of 29) of PIK3CA exon 1-7 mutations observed in our study. Interestingly, we observed differences in the level of AKT phosphorylation associated with these mutations. Expression of the p110α-G106R, -G106V and -delP449-455 mutants led to higher levels of phospho-AKT Here we found that almost all mutations in exons 1-7 localized within the ABD, the ABD-RBD linker region, and the C2 domain of p110α whereas very few mutations localized within the RBD, which binds RAS. This pattern is reminiscent of the distribution of rare exon 1-7 mutations that have been reported in colorectal, breast, and bladder cancers (20) . As was previously shown for PIK3CA exons 9-20 mutations (26), we found that PIK3CA exons 1-7 mutations could co-exist with PTEN and KRAS mutants in both EECs and NEECs.
The high frequency, and non-random distribution of amino terminal p110α mutants in EECs and NEECs infers that there is a selective advantage to mutationally disrupting the ABD, the ABD-RBD linker, and the C2 domain of p110α in endometrial carcinomas.
Consistent with this idea, 62% of the 29 individual mutations we found in exons 1-7 of PIK3CA, encode gain-of-function mutants of p110α; eight mutations were shown in this study to be gain-of-function mutants that lead to increased levels of phospho-AKT
Ser473
, and ten additional mutations were previously shown by others to be gain-of-function mutations (33, 37) .
Approximately one-third of all nonsynonymous mutations present among the 108 endometrial tumors in this study localized within the ABD and proximal ABD-RBD linker region. Strikingly, within these two regions Arg88, Arg 93, and Lys111 residues formed mutational hotspots that accounted for 21% (6 of 29) of all mutations in EECs and 24% (7 of 29) of all mutations in NEECs in our tumor series. 
Each of the mutations at Arg88 resulted in an amino acid substitution of arginine for glutamine (R88Q), a known gain-of-function mutant associated with increased AKT activation in vitro (33) . Our finding that R88Q is a hotspot in endometrial cancer confirms previous observations by Oda et al., and Dutt et al., in which R88Q constituted 40% (6 of 15)
of PIK3CA mutations present among 53 endometrial tumors and cell-lines (33, 34) . Arg88 lies on a highly conserved surface of the ABD (40) and it forms a hydrogen bond with Asp746 in the kinase domain of p110α (23) . It has therefore been proposed that mutations at Arg88 might disrupt this interaction resulting in an altered kinase domain conformation and increased enzymatic activation of PI3K (23).
Arg93 (R93) formed a second hotspot within the ABD in our tumor series. Two different mutations were found at this reside, R93W and R93Q. Here, we characterized these two mutants functionally and showed that R93W mutation is a gain-of function mutant that leads to increased phosphorylation of AKT on serine 473. In contrast, we observed no evidence for an increase in AKT phosphorylation associated with the R93Q mutant. This was somewhat unexpected because R93Q was mutated in three different endometrial tumors in our study, strongly suggesting that it would have a selective advantage. Interestingly however, each of the three tumors that harbored the R93Q mutant also had at least one other PIK3CA mutation in a different domain of p110α (either T1025N, H1047Y/K111N, or A1066V), whereas tumors with the activating the R93W mutant had no other p110α mutation. Our observation that R93Q always occurs as a "double" or "triple" mutant could be functionally relevant because Zhao and Vogt (41) have shown that two mutations occurring in different domains of p110α can functionally synergize and activate PI3K more potently than either mutation alone. We therefore speculate that the p110α-R93Q mutant might be only weakly activating by itself, below the level of detection in the assays performed here, but that it cooperates with kinase domain mutations to synergistically activate PI3K. Future studies examining the combinatorial effects of the R93Q and its co-occurring mutations will be required to test this hypothesis. However, consistent with the idea that mutations in different domains of p110α can functionally co-operate, the vast majority of endometrial tumors that had two or more PIK3CA mutations in this study had mutations in different domains of p110α.
In addition to R88 and R93 hotspots, another residue in the ABD, at position 106 (G106), was recurrently mutated in endometrial cancer. We found that both mutations at this site (G106R and G106V) were gain-of-function mutants that increased AKT phosphorylation. It is currently unclear how mutations at this residue affect p110α activity since structural studies have not revealed a specific interaction mediated by residue 106 (23) .
The third mutation hotspot in the amino terminus of p110α occurred at lysine 111 (K111). One endometrial tumor had a K111N mutation and two additional endometrial tumors had a K111E mutation. Here we showed that the K111E mutant is activating, leading to an increase in AKT phosphorylation compared to wildtype p110α. We observed that the level of phospho-AKT associated with the K111E was lower than for the H1047R mutant.
This observation is consistent with the findings of Gymnopoulous et al., that the K111N mutant of p110α is more weakly activating than the H1047R kinase domain mutant (37) .
The C2 domain of p110α harbored 13% of all nonsynonymous PIK3CA mutations among the endometrial tumors analyzed in this study. Of the eight individual mutations in the C2 domain, three mutations (E365K in 2 cases, and C420R in one case) were previously shown to be activating (33, 37) . Here we tested the functional consequences of the other five C2 domain mutants that had not been previously characterized. We showed that the delP449-L455 and E453K mutants were activating. Both of these mutants increased AKT phosphorylation at levels similar to, or greater than, the strongly activating H1047R kinase domain mutant. Both p110α-Glu453 and the adjacent residue Glu454, form hydrogen bonds with p85α-Glu348 (39) . It is therefore likely that the delP449-L455 and E453K mutants disrupt this interaction thus leading to increased catalytic activity. Interestingly we observed that the p110α-delP449-L455 deletion mutant led to much higher levels of phosphorylated AKT than the p110α-E453K point mutant. We speculate that higher level of AKT activation seen with the p110α-delP449-L455 deletion mutant might reflect an additive effect of mutating the p110α-Glu453 and Glu454, both of which form hydrogen bonds with p85α, whereas the E453K point mutant affects only one of these residues. Although we found no convincing biochemical evidence that the p110α-V344R, -G364R, and -E453A C2-domain mutants were activating as single mutants, it remains possible that they might contribute to endometrial tumorigenesis via AKT-independent mechanisms (11), or, in the case of p110α-V344R and p110α-G364R, which co-occur with other PIK3CA mutations, by co-operating with other p110α mutants. Alternatively, these mutants might be bystander mutations that have no selective advantage to tumorigenesis.
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